Evidence map›Paper›PMID 33124216›Full record

ArticleInfection & chemotherapy2020

Fosfomycin Dosing Regimens based on Monte Carlo Simulation for Treated Carbapenem-Resistant

Sukrit Kanchanasurakit, Wichai Santimaleeworagun, Charles E McPherson, Napacha Piriyachananusorn, Benjawan Boonsong, Papanin Katwilat, Surasak Saokaew

Open access · goldAbstract read
In one paragraph

Article in Infection & chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. The burden of carbapenem-resistantFrontiers in pharmacology · 2022
    Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 3 countries.

Sukrit KanchanasurakitDivision of Pharmacy Practice, Department of Pharmaceutical Care, School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand.ORCID https://orcid.org/0000-0002-1268-2665
Wichai SantimaleeworagunPharmaceutical Initiative for Resistant Bacteria and Infectious Diseases Working Group (PIRBIG), Nakorn Pathom, Thailand.ORCID https://orcid.org/0000-0001-9974-957X
Charles E McPhersonCollege of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0002-5062-9320
Napacha PiriyachananusornDivision of Pharmaceutical care, Department of Pharmacy, Phrae Hospital, Phrae, Thailand.ORCID https://orcid.org/0000-0001-5125-309X
Benjawan BoonsongDivision of Pharmaceutical care, Department of Pharmacy, Phrae Hospital, Phrae, Thailand.ORCID https://orcid.org/0000-0002-7697-013X
Papanin KatwilatDivision of Infectious Disease, Department of Medicine, Phrae Hospital, Phrae, Thailand.ORCID https://orcid.org/0000-0001-7938-8666
Surasak SaokaewDivision of Pharmacy Practice, Department of Pharmaceutical Care, School of Pharmaceutical Sciences, University of Phayao, Phayao, Thailand.ORCID https://orcid.org/0000-0002-1382-0660
Monash University Malaysia · MYSilpakorn University · THUniversity of Illinois Chicago · USUniversity of Phayao · THVajira Hospital · TH

Funding

University of Phayao
6 · The paper itself

Abstract

backgroundInfections by Carbapenem-Resistant MATERIALS AND

methodsFosfomycin MIC was defined by the E-test method. We used Fosfomycin pharmacokinetic parameters from a previously published study. The percent of the time period in which the drug concentration exceeded the MIC, or %T>MIC, used in this study were determined to be 70% of T>MIC and 100% of T>MIC, respectively. All dosing regimens were estimated for the probability of target attainment using a Monte Carlo simulation.

resultsIn this study, we found the MIC's of fosfomycin against CRE isolates ranged from 8 mg/L to 96 mg/L. The total daily dose of fosfomycin ranged from 16 - 24 g and was administered utilizing various fosfomycin dosing regimens to achieve the pharmacokinetic/pharmacodynamic (PK/PD) target in pathogens with a MIC of 32 mg/L for 70%T>MIC and a MIC of 12 mg/L for 100%T>MIC, respectively. For the twelve patients who received the recommended fosfomycin dosing regimen, eleven achieved bacterial eradication for a microbiological cure rate of 91%; and of those patients achieving eradication, two died despite having negative cultures for CRE; the one remaining patient had bacterial persistence. The most commonly observed adverse drug reactions were hypernatremia (3 cases) and hypokalemia (3 cases) and acute kidney injury (3 cases).

conclusionOur findings suggest fosfomycin has tended to good efficacy when using dosing regimens that achieve the PK/PD target. Nonetheless, further validation of these regimens in larger populations is needed.

Indexed as

Carbapenem-Resistant EnterobacteriaceaeFosfomycinMicrobial sensitivity testsMonte Carlo

Identifiers

PMID33124216
PMCPMC7779995
OpenAlexW3096249683

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.